• to lower the potential risk of serious cardiovascular (coronary heart and blood vessel) challenges in Older people with kind 2 diabetes and cardiovascular diseaseThis led Novo Nordisk to conduct more investigate into increased dosages of semaglutide specifically for weight administration.$100 billion. That’s exactly how much the weight loss d